iBio Inc (IBIO)

[guay]

William Treat, chief manufacturing officer at the federally funded Texas A&M Center for Innovation in Advanced Development and Manufacturing, said its facilities will produce between 300 million and 500 million doses of vaccine for Novavax and other companies selected by Warp Speed. The site, which was created in the wake of the 2009 H1N1 flu pandemic, was originally designed to manufacture 50 million doses of flu vaccine.
Several contract manufacturers said their facilities could potentially switch from making one vaccine to another in about a month, or three to five months if additional equipment has to be ordered. That flexibility is crucial because it’s unlikely that all of the candidates in late-stage trials will pan out.